AMD3100 Inhibits Epithelial–mesenchymal Transition, Cell Invasion, and Metastasis in the Liver and the Lung Through Blocking the SDF‐1α/CXCR4 Signaling Pathway in Prostate Cancer

Wen-Bin Zhu,Zhi-Feng Zhao,Xin Zhou
DOI: https://doi.org/10.1002/jcp.27831
2018-01-01
Journal of Cellular Physiology
Abstract:Stromal cell-derived factor-1 (SDF-1) and CXC chemokine receptor 4 (CXCR4) have been found to be tightly correlated with the progression of prostate cancer (PC). In this study, we investigated the effects of an SDF-1/CXCR4 inhibitor, AMD3100, on cell progression and metastasis potential of human PC cells. Human PC cell lines (LNCaP, PC3, and DU145) were cultured to detect SDF-1/CXCR4, which showed higher SDF-1 and CXCR4 expression than the normal human prostate epithelial cell line, RWPE-1. AMD3100 was confirmed to be an inhibitor of SDF-1, and to detect the effect of SDF-1/CXCR4 inhibition on PC, PC cells were treated with AMD3100 or/and CXCR4 siRNA. The results suggested that inhibition of the SDF-1/CXCR4 pathway could promote the E-cadherin level but inhibit the levels of invasion and migration of vimentin, N-cadherin and 51 integrin. Finally, tumor formation in nude mice was conducted, and the cell experiment results were verfied. These data show that AMD3100 suppresses epithelial-mesenchymal transition and migration of PC cells by inhibiting the SDF-1/CXCR4 signaling pathway, which provides a clinical target in the treatment of PC.
What problem does this paper attempt to address?